Quest Diagnostics Granted FDA Breakthrough Designation For Its Adeno-Associated Virus Test
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics has been granted FDA breakthrough designation for its Adeno-Associated Virus (AAV) test. Additionally, Quest has expanded its collaboration with Sarepta Therapeutics to develop AAV Companion Diagnostics for Sarepta's gene therapies.
August 30, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics' FDA breakthrough designation for its AAV test and expanded collaboration with Sarepta Therapeutics could potentially boost its stock in the short term.
The FDA breakthrough designation is a significant regulatory milestone that could enhance the company's reputation and market position. The expanded collaboration with Sarepta Therapeutics could open up new revenue streams.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100